MedTrace Logo

A Multi-center 12-week Study of HMS5552 in T2DM

NCT02561338 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 258

Last updated 2020-03-10

Study results available
· View outcomes & findings →

Summary

This study evaluates the safety, tolerability, efficacy and population PK of HMS5552 in type 2 diabetic adult subjects,there will be 5 groups ,4 groups will receive HMS5552,while 1 will receive placebo.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

HMS5552

75mgQD

DRUG

HMS5552

100mgQD

DRUG

HMS5552

50mgBID

DRUG

HMS5552

75mgBID

OTHER

Placebo

QD/BID

Sponsors & Collaborators

  • Tigermed Consulting Co., Ltd

    collaborator INDUSTRY

  • Hua Medicine Limited

    lead INDUSTRY

Principal Investigators

  • Dalong Zhu, MD，PhD · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02561338 on ClinicalTrials.gov